Dr John Fahy UCSF

Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...

VERU Inc. (VERU) $24. High Risk, Minimal Reward?

Pre-FDA Approval Play. The Shares Are Now in the Hands of Fast Money Traders. You Can't Kiss all the...

Revive Therapeutics (RVVTF) Enters the Danger Zone.

What Danger You Ask? Danger #1, the FDA doesn't like the data, and you own the stock.

Smart for Life (SMFL) Capitulates?

We Are Long Term Bullish on Smart for Life. After a Volatile Post IPO Trading, we may Have Seen the Bottom....
ehave

Ehave, Inc. Announces its KetaDASH Mobile Unit Delivered to Miami Beach.

MIAMI, June 03, 2022 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced...

Smart for Life (SMFL) $0.43 on Track to Close Pending Acquisition of Ceautamed Worldwide.

Has Smart for Life Found a Base at $0.45? Market Action Aside, We Think So. Report Out Monday.

Ohio State University Completes Study on Pressure Bioscience (PBIO) and Protein Drinks.

Pressure BioSciences' Ultra Shear Technology Positioned for Critical Enabling Role in Global $41 Billion (2027) Plant Protein Beverage Market.

Revive’s Quarterly Report, Discussion, and a Video!

With 5,000 hospitalizations reported daily (150,000 a month), contracting Covid is not something to be taken lightly - after you get it....
Revive Therapeutics

Revive Therapeutics Gains 25% on Positive FDA Comments.

The Company stated yesterday that it "has received positive comments from the FDA in regard to the Company’s request to determine and...

Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?

Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...

Latest article

Nine Page Summary Report on GeoVax (GOVX)

This is a great long-term story. We’re telling you. (March 2024) When we finished writing our earlier...

GeoVax (GOVX) Provides First Half 2024 Business Update.

Award of BARDA Project NextGen contract represents a significant milestone event; Total value...

Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.

Can You Imagine Selling Solgenix at $2.00 yesterday. And to be honest, news wasn't all that big - such...